<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://test.ccga.io/index.php?action=history&amp;feed=atom&amp;title=HAEM4%3AAcute_Myeloid_Leukemia_%28AML%29%2C_Not_Otherwise_Specified</id>
	<title>HAEM4:Acute Myeloid Leukemia (AML), Not Otherwise Specified - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://test.ccga.io/index.php?action=history&amp;feed=atom&amp;title=HAEM4%3AAcute_Myeloid_Leukemia_%28AML%29%2C_Not_Otherwise_Specified"/>
	<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Acute_Myeloid_Leukemia_(AML),_Not_Otherwise_Specified&amp;action=history"/>
	<updated>2026-06-17T09:45:35Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.5</generator>
	<entry>
		<id>https://test.ccga.io/index.php?title=HAEM4:Acute_Myeloid_Leukemia_(AML),_Not_Otherwise_Specified&amp;diff=13221&amp;oldid=prev</id>
		<title>Bailey.Glen at 21:27, 4 December 2023</title>
		<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Acute_Myeloid_Leukemia_(AML),_Not_Otherwise_Specified&amp;diff=13221&amp;oldid=prev"/>
		<updated>2023-12-04T21:27:23Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 16:27, 4 December 2023&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l14&quot;&gt;Line 14:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 14:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==WHO Classification Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==WHO Classification Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myeloid Leukemia (AML) &lt;/del&gt;with &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Minimal Differentiation&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myeloid leukaemia &lt;/ins&gt;with &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;minimal differentiation&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myeloid Leukemia (AML) &lt;/del&gt;without &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Maturation&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myeloid leukaemia &lt;/ins&gt;without &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;maturation&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myeloid Leukemia (AML) &lt;/del&gt;with &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Maturation&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myeloid leukaemia &lt;/ins&gt;with &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;maturation&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Myelomonocytic Leukemia&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;myelomonocytic leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Monoblastic and Monocytic Leukemia&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;monocytic leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Pure Erythroid Leukemia&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:Acute erythroid leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Megakaryoblastic Leukemia (AMKL)&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;megakaryoblastic leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Basophilic Leukemia&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM5:&lt;/ins&gt;Acute &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;basophilic leukaemia&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[Acute Panmyelosis with Myelofibrosis]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;#[[&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;HAEM4:&lt;/ins&gt;Acute Panmyelosis with Myelofibrosis]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Other Related Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Other Related Pages (Includes Links to Content)==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Bailey.Glen</name></author>
	</entry>
	<entry>
		<id>https://test.ccga.io/index.php?title=HAEM4:Acute_Myeloid_Leukemia_(AML),_Not_Otherwise_Specified&amp;diff=12410&amp;oldid=prev</id>
		<title>Bailey.Glen: Created page with &quot;==Primary Author(s)*==  M. Anwar Iqbal, Ph.D., FFACMG  __TOC__  ==General Disease Overview / Description of Cancer Category==  The category &quot;AML Not Otherwise Specified&quot; or &quot;A...&quot;</title>
		<link rel="alternate" type="text/html" href="https://test.ccga.io/index.php?title=HAEM4:Acute_Myeloid_Leukemia_(AML),_Not_Otherwise_Specified&amp;diff=12410&amp;oldid=prev"/>
		<updated>2023-11-03T18:05:30Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Primary Author(s)*==  M. Anwar Iqbal, Ph.D., FFACMG  __TOC__  ==General Disease Overview / Description of Cancer Category==  The category &amp;quot;AML Not Otherwise Specified&amp;quot; or &amp;quot;A...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Primary Author(s)*==&lt;br /&gt;
&lt;br /&gt;
M. Anwar Iqbal, Ph.D., FFACMG&lt;br /&gt;
&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
==General Disease Overview / Description of Cancer Category==&lt;br /&gt;
&lt;br /&gt;
The category &amp;quot;AML Not Otherwise Specified&amp;quot; or &amp;quot;AML-NOS&amp;quot;, as described in the revised 4th edition of the WHO&amp;lt;ref name=&amp;quot;:0&amp;quot;&amp;gt;Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p156-166.&amp;lt;/ref&amp;gt;, includes eight specific subtypes based on examination of bone marrow aspirates and trephine biopsies as well as peripheral blood smears: AML with Minimal Differentiation, AML with Maturation, AML without Maturation, Acute Myelomonocytic Leukemia, Acute Monoblastic and Monocytic Leukemia, Pure Erythroid Leukemia, Acute Megakaryoblastic Leukemia (AMKL), Acute Basophilic Leukemia, and Acute Panmyelosis with Myelofibrosis.  Links to these subtypes are listed below in the &amp;quot;WHO Classification Pages&amp;quot; section.  The subtypes in the AML-NOS category do &amp;#039;&amp;#039;not&amp;#039;&amp;#039; meet the criteria for inclusion in any of the other AML categories (i.e. AML with Recurrent Genetic Abnormalities, AML with Myelodysplasia-Related Changes, or Therapy-Related Myeloid Neoplasms)&amp;lt;ref name=&amp;quot;:0&amp;quot; /&amp;gt;.  The 2016 revised WHO classification removed from AML-NOS the subcategory Acute Erythroid Leukemia, Erythroid/Myeloid Type&amp;lt;ref&amp;gt;{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert|last4=Thiele|first4=Jürgen|last5=Borowitz|first5=Michael J.|last6=Le Beau|first6=Michelle M.|last7=Bloomfield|first7=Clara D.|last8=Cazzola|first8=Mario|last9=Vardiman|first9=James W.|date=2016|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|url=https://www.ncbi.nlm.nih.gov/pubmed/27069254|journal=Blood|volume=127|issue=20|pages=2391–2405|doi=10.1182/blood-2016-03-643544|issn=1528-0020|pmid=27069254}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
AML-NOS is a diagnosis of exclusion, requiring mutation and cytogenetic analyses to identify prognostically significant genetic alterations which appear to be independent of the morphologic subtypes&amp;lt;ref name=&amp;quot;:0&amp;quot; /&amp;gt;. If AML with &amp;#039;&amp;#039;NPM1&amp;#039;&amp;#039; and &amp;#039;&amp;#039;CEPBA&amp;#039;&amp;#039; are ruled out, the subgroups of AML-NOS are not prognostically significant, with the potential exception of [Pure Erythroid Leukemia&amp;lt;ref name=&amp;quot;:0&amp;quot; /&amp;gt;.  No chromosomal abnormalities have been identified to define AML-NOS specifically; inclusion in the AML-NOS category is primary due to examination of the leukemic cells for morphological and immunophenotypic features&amp;lt;ref name=&amp;quot;:0&amp;quot; /&amp;gt;. Evaluation of mutational status beyond NPM1 and CEPBA is also important, as reflected by a recent study that found 15% of AML-NOS cases have a RUNX1 mutation which is associated with an intermediate risk&amp;lt;ref&amp;gt;{{Cite journal|last=You|first=Eunkyoung|last2=Cho|first2=Young-Uk|last3=Jang|first3=Seongsoo|last4=Seo|first4=Eul-Ju|last5=Lee|first5=Jung-Hee|last6=Lee|first6=Je-Hwan|last7=Lee|first7=Kyoo-Hyung|last8=Koh|first8=Kyung-Nam|last9=Im|first9=Ho Joon|date=2017|title=Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified|url=https://www.ncbi.nlm.nih.gov/pubmed/28927163|journal=American Journal of Clinical Pathology|volume=148|issue=1|pages=64–72|doi=10.1093/ajcp/aqx046|issn=1943-7722|pmid=28927163}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
==WHO Classification Pages (Includes Links to Content)==&lt;br /&gt;
&lt;br /&gt;
#[[Acute Myeloid Leukemia (AML) with Minimal Differentiation]]&lt;br /&gt;
#[[Acute Myeloid Leukemia (AML) without Maturation]]&lt;br /&gt;
#[[Acute Myeloid Leukemia (AML) with Maturation]]&lt;br /&gt;
#[[Acute Myelomonocytic Leukemia]]&lt;br /&gt;
#[[Acute Monoblastic and Monocytic Leukemia]]&lt;br /&gt;
#[[Pure Erythroid Leukemia]]&lt;br /&gt;
#[[Acute Megakaryoblastic Leukemia (AMKL)]]&lt;br /&gt;
#[[Acute Basophilic Leukemia]]&lt;br /&gt;
#[[Acute Panmyelosis with Myelofibrosis]]&lt;br /&gt;
&lt;br /&gt;
==Other Related Pages (Includes Links to Content)==&lt;br /&gt;
&lt;br /&gt;
Put your text here&lt;br /&gt;
&lt;br /&gt;
==Additional Information==&lt;br /&gt;
&lt;br /&gt;
Put your text here&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Notes==&lt;br /&gt;
&amp;lt;nowiki&amp;gt;*&amp;lt;/nowiki&amp;gt;Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;*&amp;lt;/nowiki&amp;gt;The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Category:Recently Added Pages]]&lt;/div&gt;</summary>
		<author><name>Bailey.Glen</name></author>
	</entry>
</feed>